Archives
-
CAY10499: A Precision Tool for Lipid Flux
2026-08-29
CAY10499, an inhibitor of human hormone sensitive lipase, enables mechanistic separation of lipid hydrolysis from ACLY-driven lipid synthesis. This article presents a practical framework for applying the compound to enzyme, immunometabolic, steroidogenesis, and atherosclerosis research without overstating evidence from tumor models.
-
Y-27632 for ROCK and Ribotoxic Stress Assays
2026-08-28
Y-27632 is a selective ROCK inhibitor for separating cytoskeletal effects from ribotoxic-stress responses. This article connects ROCK pathway experimentation with the JNK–USP36–Snail1 findings that explain resistance to ribosome-targeting stress in solid tumor models.
-
Machine-Learning LNP Design for Microglia Reprogramming
2026-08-28
Rafiei, Shojaei, and Chau combined a 216-formulation lipid nanoparticle library with supervised machine learning to identify carriers that both deliver mRNA and alter inflammatory microglial phenotypes. Their HA-LNP2 formulation improved IL10 expression and reduced TNF-α in activated murine and human iPSC-derived microglia, while the study also defines important limits for model transferability.
-
CAY10499: A Lipid Flux Tool for TAM Assays
2026-08-27
CAY10499, an inhibitor of human hormone sensitive lipase, provides a mechanistic way to separate lipid hydrolysis from EV-driven metabolic programming in tumor-associated macrophage studies. This article translates ACLY–palmitate findings into practical assay design, controls, and interpretation strategies.
-
Rex Biosensor Maps Bacterial NADH/NAD+ Redox State
2026-08-27
The reference study introduced a genetically encoded, ratiometric NADH/NAD+ biosensor by coupling redox-responsive Rex regulation to a fluorescent reporter. Its ability to resolve respiratory-chain and carbon-source effects, and to enrich rare high-NADH cells, demonstrates how regulatory biosensors can complement conventional biochemical assays in bacterial metabolic research.
-
SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis
2026-08-26
The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced renal fibrosis and inflammation. By combining inhibitor treatment in a chronic kidney disease model with tubular epithelial-cell experiments, it connects SMYD2 activity to epithelial–mesenchymal transition, extracellular-matrix accumulation, and Smad3/STAT3 signaling.
-
EZ Cap™ Firefly Luciferase mRNA for Assays
2026-08-26
EZ Cap™ Firefly Luciferase mRNA enables sensitive reporter expression for gene regulation, delivery, and in vivo imaging studies. This article explains how Cap1 and poly(A) design can turn a luciferase transcript into a practical tool for separating delivery, translation, and cellular stress effects.
-
From Delivery to Function: A Better mRNA Readout
2026-08-25
Translational mRNA research increasingly depends on distinguishing cellular uptake from productive protein expression. This thought-leadership article examines how EZ Cap™ Cy5 EGFP mRNA (5-moUTP) and its dual Cy5/EGFP readout can strengthen delivery studies, inform formulation decisions, and extend lessons from β cell-targeted lipid nanoparticles to broader gene regulation and function studies.
-
IDO1 Blockade and Tumor-Intrinsic JAK2/STAT3
2026-08-25
This study uses single-cell RNA sequencing to show that pharmacological apo-IDO1 inhibition can activate antitumor immune cells while also promoting M2 macrophage infiltration and IL-6-dependent JAK2/STAT3 signaling in tumor cells. The findings provide a mechanistic explanation for unexpected limits of IDO1 inhibitor therapy and support testing combined IDO1 and JAK2/STAT3 blockade.
-
SM-102: Designing Better mRNA Delivery Decisions
2026-08-24
A mechanistic and translational framework for positioning SM-102 in lipid nanoparticle development, integrating machine learning evidence, formulation controls, product handling, competitive benchmarking, and responsible next-step strategy.
-
EZ Cap™ Firefly Luciferase mRNA Workflow Guide
2026-08-24
Use EZ Cap™ Firefly Luciferase mRNA as a sensitive, transient reporter for cell-based translation studies, gene regulation assays, and in vivo bioluminescence imaging. A practical LNP-sizing strategy, informed by recent manufacturing research, helps separate delivery-process effects from reporter biology.
-
Azathramycin A: Degradation-Aware TB Assays
2026-08-23
Azathramycin A is a macrolide antibiotic with value in tuberculosis research, but its degradation behavior must be treated as an assay variable. This guide connects ribosome-focused pharmacology, impurity analysis, and resistance-aware experimental design for more interpretable Mtb studies.
-
Metal-Ion Enrichment for Higher-Loading mRNA Vaccines
2026-08-22
The reference study introduces a manganese-mediated condensation strategy that creates a dense mRNA core before lipid coating, nearly doubling mRNA loading relative to conventional LNP-mRNA formulations. The resulting L@Mn-mRNA system also improves cellular uptake and vaccine responses while potentially reducing lipid-associated and anti-PEG immune liabilities.
-
N1-Methylpseudouridine: mRNA Workflow Guide
2026-08-22
N1-Methylpseudouridine supports higher mRNA protein output while helping limit innate immune and eIF2α-linked translational suppression. This practical guide connects nucleoside selection with cell-based validation, metabolic-state controls, and troubleshooting for reproducible mRNA experiments.
-
Malate Workflows for TCA and Tumor Immunometabolism
2026-08-21
Use malate as a controlled metabolic perturbation, a malate dehydrogenase substrate, and a practical comparator for studying mitochondrial redox and tumor–macrophage crosstalk. This workflow distinguishes what the cholangiocarcinoma evidence demonstrates from what malate can help researchers test next.